Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 Mn;CT4lv[XOnIFHzd4F6 MXKzNEBucW5? MlHFTY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP M17ZN|E6QDh6N{[w
Jurkat M3\zWmtqdmG|ZTDBd5NigQ>? MmPvPVYhcA>? MlnQSG1UVw>? NF3PdWhKdmirYnn0bY9vKG:oIGDBVnAyKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTD3bZRpKEWFNUCgc4YhOyEQvF2= M3rNWFI{QDVyMUm5
Capan1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXUO|IhcA>? MnrzSG1UVw>? NXnkUZNVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDWkODMjDn[Y5mKG23dHH0[YQhcHWvYX6gR4Fx[W5zIHPlcIx{KHerdHigTWM2OCCxZjCzPU44KM7:TR?= NGO2UJIzPDN7OEO4Ny=>
DT40 NVW5O|U6S3m2b4TvfIlkKEG|c3H5 M4jOPVczKGh? NYj4SoZZTE2VTx?= Mmr6R5l1d3SxeHnjbZR6KGGpYXnud5Qh[2irY3vlckBDWkODMj3k[YZq[2mnboSgSHQ1OCClZXzsdy=> M3LReFI1QTJ{NUi3
ML-1 MXfBdI9xfG:2aXOgRZN{[Xl? MX[yMlUh|ryP NEXSdVMzPCCq MojUSG1UVw>? MlnSV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= NH;TRpMzPDh7NUGzOS=>
HCT-116 NUPycYNZU2mwYYPlJGF{e2G7 MXewMlUh|ryP MYKyOEBp MXXQRXJRKGGldHn2bZR6KGSnY4LlZZNmew>? M3;uZ|I{ODV2MkGz
UM-SCC1 MkTHR5l1d3SxeHnjJGF{e2G7 MYmxNEDPxE1? NIDZO48zPCCq NH7w[oNT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> M1;jW|IyQTF{NkKw
FaDu NY\ScJJSS3m2b4TvfIlkKEG|c3H5 Mn71NVAh|ryP NHTRZ24zPCCq M{\kenJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 M{TRWFIyQTF{NkKw
PC-3 NYqxUWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnZXIoyOCEQvF2= MnXvTY5lfWOnczDhJJNq\26rZnnjZY51KGmwaHnibZRqd25iaX6gZ49td267IH\vdo1ifGmxbtMg NFPQbo8zOTV5MUmxNi=>
EoL-1-cell MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwMEe5PEDPxE1? MnzOV2FPT0WU
NCI-SNU-5 NWH1UZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe5SXdKSzVyPUOuNVI5PDFizszN MlLqV2FPT0WU
BV-173 NHnpRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\TTWM2OD13LkS1OFA6KM7:TR?= M2nhcHNCVkeHUh?=
HCC1806 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTVwN{WxO|Mh|ryP M1jqSXNCVkeHUh?=
COLO-680 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTXVG1KSzVyPU[uNlE1ODZizszN Mn;HV2FPT0WU
HCC2218 NYTabGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP2Wo9nUUN3ME23Mlc6PzB2IN88US=> MofiV2FPT0WU
SK-MEL-24 NVvBTng3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvaTWM2OD15LkixPVI1KM7:TR?= NILHO2JUSU6JRWK=
NCI-H720 M{\hOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\mOmlKSzVyPUiuOFM3ODNizszN MWrTRW5ITVJ?
KASUMI-1 M{TzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zjNWlEPTB;OD64PVI3PiEQvF2= NFTOc|JUSU6JRWK=
HAL-01 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u3cmlEPTB;OT64PFYzKM7:TR?= NF7ZVmJUSU6JRWK=
CAL-33 NF7CR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ITWM2OD1zMD60N|Qh|ryP Ml35V2FPT0WU
SK-MEL-1 M3\EeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fxNGlEPTB;MUKuOFY3OyEQvF2= M33MO3NCVkeHUh?=
Ramos-2G6-4C10 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF{LkS3OVIh|ryP NXjQb5NuW0GQR1XS
KY821 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H4T2lEPTB;MUKuOFg2KM7:TR?= MWLTRW5ITVJ?
HEC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF{LkmxPVYh|ryP MnrZV2FPT0WU
SK-NEP-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{joTGlEPTB;MUOuNVY3KM7:TR?= MoLtV2FPT0WU
MN-60 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK5eIlUUUN3ME2xN{42Ozh7IN88US=> MoOwV2FPT0WU
DU-145 NV7MUXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrYU2tKSzVyPUGzMlkxPTNizszN MkC5V2FPT0WU
EW-3 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1cGlEPTB;MUSuOVU3PSEQvF2= NFXnS4hUSU6JRWK=
OS-RC-2 M4nPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33BTWlEPTB;MUWuPVU5QSEQvF2= MX;TRW5ITVJ?
RPMI-8226 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF4LkKwOFIh|ryP MXvTRW5ITVJ?
ChaGo-K-1 NXX2eYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH1TJFKSzVyPUG2MlU{OjVizszN Ml2wV2FPT0WU
DEL M2TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD3PJVZUUN3ME2xOk43PzF5IN88US=> M2rkOHNCVkeHUh?=
GP5d M4jmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF5LkC1N{DPxE1? NFvkVYpUSU6JRWK=
COLO-668 NWDkPZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13kRWlEPTB;MUeuOlI6PCEQvF2= Mn\KV2FPT0WU
H9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv4TWM2OD1zOD6yPFM{KM7:TR?= MnL6V2FPT0WU
NKM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z2XGlEPTB;MUiuOVEyQSEQvF2= NF3SOYlUSU6JRWK=
KYSE-150 NF;6XW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnMVWlLUUN3ME2xPE46QTh4IN88US=> MX\TRW5ITVJ?
Daoy M13nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTRWXdoUUN3ME2xPU42PjR7IN88US=> NHfBWHFUSU6JRWK=
ECC10 NF;WR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnBRXJkUUN3ME2yNE44PDV3IN88US=> M4\KbXNCVkeHUh?=
A388 NXG5[FFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7IZm8xUUN3ME2yNU46ODlzIN88US=> NVvIb|JYW0GQR1XS
MHH-NB-11 M3H1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPGclNmUUN3ME2yN{4yOzZ|IN88US=> M{\RN3NCVkeHUh?=
HCC1937 M{T1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36y[2lEPTB;MkSuO|Q3KM7:TR?= NXLMOIZRW0GQR1XS
TGBC11TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH36O5NKSzVyPUK1MlY5PjNizszN NGrhXXRUSU6JRWK=
CTV-1 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ3Lki5Olkh|ryP M3i3OHNCVkeHUh?=
NCI-H2029 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\VTWM2OD1{Nj60NlM5KM7:TR?= MofxV2FPT0WU
HLE MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG1UphKSzVyPUK3MlA2PCEQvF2= Ml7UV2FPT0WU
NCI-H1693 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTG[HlnUUN3ME2yO{4zQDl6IN88US=> MVPTRW5ITVJ?
HCC70 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK0TWM2OD1{Nz63NlQ3KM7:TR?= MYLTRW5ITVJ?
BEN MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[wTWM2OD1{Nz65OVY3KM7:TR?= MkftV2FPT0WU
LB771 NWj4SmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH5OZdKSzVyPUK4Mlg{PzNizszN NG\OeWRUSU6JRWK=
697 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLFTWM2OD1{OT6wNlM2KM7:TR?= MUPTRW5ITVJ?
LU-139 M2\IcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vh[2lEPTB;MkmuN|c1QCEQvF2= Mm\6V2FPT0WU
EW-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPDbIJDUUN3ME2yPU4{QDF2IN88US=> NIrkWG5USU6JRWK=
MOLT-13 NYDpNFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1{OT6zPFE1KM7:TR?= M1P2WXNCVkeHUh?=
L-363 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzVTWM2OD1{OT60O|k5KM7:TR?= NIi3boRUSU6JRWK=
EM-2 NH;qZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fsXGlEPTB;MkmuOFkxOSEQvF2= MnKwV2FPT0WU
RS4-11 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfteIdKSzVyPUOwMlQzPDFizszN NVTqW2RyW0GQR1XS
A2780 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNyLke0OVch|ryP Mk\RV2FPT0WU
KU812 M3GwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK1W3NKSzVyPUOyMlM3PDJizszN NVHPU2JSW0GQR1XS
COLO-684 NETVZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTN|LkO1PVkh|ryP NWTR[WhiW0GQR1XS
MFE-280 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN|LkO4PFkh|ryP NV3U[2hkW0GQR1XS
KG-1 NIjZWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TFbmlEPTB;M{OuOlAxOSEQvF2= Mly1V2FPT0WU
JVM-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3SZJHUUN3ME2zOU42QDZ6IN88US=> NYDVdohXW0GQR1XS
MV-4-11 NYrxdm12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P5W2lEPTB;M{WuPFQ6QSEQvF2= NEC4PWJUSU6JRWK=
LAMA-84 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lp[WlEPTB;M{[uO|M1PSEQvF2= MnXkV2FPT0WU
MOLT-16 NWPMb5R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4THU2lEPTB;M{[uPVUzKM7:TR?= MUXTRW5ITVJ?
H4 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi0[45KSzVyPUO3MlU3PyEQvF2= MVrTRW5ITVJ?
T47D MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf0TWM2OD1|Nz63NFE5KM7:TR?= NX:5[XZ{W0GQR1XS
CAL-54 NUfmdG5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5TWM2OD1|Nz65OlYh|ryP M{LjcnNCVkeHUh?=
SW982 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOyTWM2OD1|OD6wPVk5KM7:TR?= M4G5N3NCVkeHUh?=
IGROV-1 NWjuOZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN7LkOzNFQh|ryP NIraSoZUSU6JRWK=
NB14 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjhdplKSzVyPUSwMlcxOzFizszN M3;GbnNCVkeHUh?=
HCC1187 NEP4cXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K1N2lEPTB;NEGuNlc4OSEQvF2= M2HkSXNCVkeHUh?=
SBC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L6UWlEPTB;NEGuN|A3OyEQvF2= MmrWV2FPT0WU
KARPAS-45 NGmwS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRzLkS4NVgh|ryP MWfTRW5ITVJ?
MOLT-4 M4PTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\6dGlEPTB;NEKuNlU{QCEQvF2= M33kUnNCVkeHUh?=
JVM-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzjTWM2OD12Mj65NlA4KM7:TR?= NUDHTIZnW0GQR1XS
A4-Fuk NHHFTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PDd2lEPTB;NEOuOVY6OSEQvF2= MVrTRW5ITVJ?
MDA-MB-361 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZVnJRUUN3ME20N{45PDF2IN88US=> NGPHcHZUSU6JRWK=
BALL-1 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmflTWM2OD12Mz65OVMzKM7:TR?= MWDTRW5ITVJ?
T98G NUDS[oZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXBZnZKSzVyPUS0Mlg2OTdizszN MmnMV2FPT0WU
Mo-T M4ruN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTRdnZkUUN3ME20OU43Ozh7IN88US=> NYDiV5p2W0GQR1XS
MHH-PREB-1 M{nlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnWmlEPTB;NEWuO|U5PSEQvF2= MUnTRW5ITVJ?
ALL-PO NVi0XYdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnJXII1UUN3ME20O{4{PzlzIN88US=> MkTwV2FPT0WU
NCI-H510A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HidWlEPTB;NEeuPVA{PCEQvF2= MoDtV2FPT0WU
ML-2 M1juWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLGTWM2OD12OT63PFU3KM7:TR?= NVHidWcyW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID